<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35337044</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Persistence of Naturally Acquired and Functional SARS-CoV-2 Antibodies in Blood Donors One Year after Infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">637</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v14030637</ELocationID><Abstract><AbstractText>The developmental course of antibodies produced after a SARS-CoV-2 infection has been insufficiently investigated so far. Therefore, the aim of this study was to investigate the dynamics of SARS-CoV-2 antibody levels against the viral nucleocapsid- and spike-protein among Austrian blood donors as a representative group of a supposedly healthy population within the first year after a SARS-CoV-2 infection. The impact of age, sex, vaccination status, AB0-blood group and awareness about the infection was evaluated. Our study shows that the level of anti-N antibodies is declining, while anti-S antibody levels remain stable. Antibodies detected were functional in vitro. Age, sex and blood group do not influence antibody dynamics. However, blood group AB shows significantly lower antibody levels and in vitro functionality compared to other blood groups. Our data reveal that one out of five individuals was not aware of a previous SARS-CoV-2 infection and that the disease course neither affects the level of antibody production nor the in vitro functionality. We also found that 14% of participants show persisting COVID-19-related symptoms for up to nine months. Our results provide valuable insights into the dynamics of the immune response after a SARS-CoV-2 infection in a representative cohort of adult blood donors in Central Europe.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nunhofer</LastName><ForeName>Verena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department for Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weidner</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Austrian Red Cross, Blood Service for Vienna, Lower Austria and Burgenland, Wiedner Hauptstra&#xdf;e 32, 1040 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoeggerl</LastName><ForeName>Alexandra Domnica</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department for Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmermann</LastName><ForeName>Georg</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8282-1034</Identifier><AffiliationInfo><Affiliation>Team Biostatistics and Big Medical Data, IDA Lab Salzburg, PMU Salzburg, Strubergasse 16, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Innovation Management, PMU Salzburg, Strubergasse 16, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badstuber</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychological Assessment, Institute of Psychology, Paris-Lodron-University of Salzburg, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grabmer</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department for Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jungbauer</LastName><ForeName>Christof</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Austrian Red Cross, Blood Service for Vienna, Lower Austria and Burgenland, Wiedner Hauptstra&#xdf;e 32, 1040 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindlbauer</LastName><ForeName>Nadja</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department for Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Held</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department for Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascariuc</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department for Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortner</LastName><ForeName>Tuulia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychological Assessment, Institute of Psychology, Paris-Lodron-University of Salzburg, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohde</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8692-886X</Identifier><AffiliationInfo><Affiliation>Department for Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spinal Cord Injury and Tissue Regeneration Centre Salzburg, PMU Salzburg, Strubergasse 21, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laner-Plamberger</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1416-6023</Identifier><AffiliationInfo><Affiliation>Department for Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spinal Cord Injury and Tissue Regeneration Centre Salzburg, PMU Salzburg, Strubergasse 21, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20204-WISS/225/197-2019</GrantID><Agency>Paracelsus Medical University</Agency><Country/></Grant><Grant><GrantID>20102-F1901166-KZP</GrantID><Agency>Paracelsus Medical University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001782" MajorTopicYN="N">Blood Donors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007159" MajorTopicYN="N">Immunologic Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AB0 blood groups</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">blood donation</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">seroprevalence</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35337044</ArticleId><ArticleId IdType="pmc">PMC8953712</ArticleId><ArticleId IdType="doi">10.3390/v14030637</ArticleId><ArticleId IdType="pii">v14030637</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO  WHO Director-General&#x2019;s Opening Remarks at the Media Briefing on COVID-19&#x2014;11 March 2020. 2020.  [(accessed on 2 March 2022)].  Available online:  https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-COVID-19---11-march-2020.</Citation></Reference><Reference><Citation>Ramesh S., Govindarajulu M., Parise R.S., Neel L., Shankar T., Patel S., Lowery P., Smith F., Dhanasekaran M., Moore T. Emerging SARS-CoV-2 variants: A review of its mutations, its implications and vaccine efficacy. Vaccines. 2021;9:1195. doi: 10.3390/vaccines9101195.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9101195</ArticleId><ArticleId IdType="pmc">PMC8537675</ArticleId><ArticleId IdType="pubmed">34696303</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., Consortium C.-G.U., et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 2021;19:409&#x2013;424. doi: 10.1038/s41579-021-00573-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. 2021.  [(accessed on 2 March 2022)].  Available online:  https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-SARS-CoV-2-variant-of-concern.</Citation></Reference><Reference><Citation>Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G., Hu Y., Tao Z.W., Tian J.H., Pei Y.Y., et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265&#x2013;269. doi: 10.1038/s41586-020-2008-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727&#x2013;733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Machhi J., Herskovitz J., Senan A.M., Dutta D., Nath B., Oleynikov M.D., Blomberg W.R., Meigs D.D., Hasan M., Patel M., et al. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J. Neuroimmune Pharm. 2020;15:359&#x2013;386. doi: 10.1007/s11481-020-09944-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-020-09944-5</ArticleId><ArticleId IdType="pmc">PMC7373339</ArticleId><ArticleId IdType="pubmed">32696264</ArticleId></ArticleIdList></Reference><Reference><Citation>Bchetnia M., Girard C., Duchaine C., Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J. Infect. Public Health. 2020;13:1601&#x2013;1610. doi: 10.1016/j.jiph.2020.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.07.011</ArticleId><ArticleId IdType="pmc">PMC7402212</ArticleId><ArticleId IdType="pubmed">32778421</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re&#x2019;Em Y., Redfield S., Austin J.P., Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J.R., Husain M., Harrison P.J. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLOS Med. 2021;18:e1003773. doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y., Dai T., Wang B., Zhang L., Zeng L.H., Huang J., Yan H., Zhang L., Zhou F. The way of SARS-CoV-2 vaccine development: Success and challenges. Signal Transduct. Target. Ther. 2021;6:387. doi: 10.1038/s41392-021-00796-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00796-w</ArticleId><ArticleId IdType="pmc">PMC8575680</ArticleId><ArticleId IdType="pubmed">34753918</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling Y., Zhong J., Luo J. Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis. J. Med. Virol. 2021;93:6486&#x2013;6495. doi: 10.1002/jmv.27203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27203</ArticleId><ArticleId IdType="pmc">PMC8426880</ArticleId><ArticleId IdType="pubmed">34264528</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M., Krammer F., Regev-Yochay G., Lustig Y., Balicer R.D. SARS-CoV-2 breakthrough infections in vaccinated individuals: Measurement, causes and impact. Nat. Rev. Immunol. 2022;22:57&#x2013;65. doi: 10.1038/s41577-021-00662-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00662-4</ArticleId><ArticleId IdType="pmc">PMC8649989</ArticleId><ArticleId IdType="pubmed">34876702</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Y., Wang W., Ma J., Wu S., Sun F. Reinfection rates among patients previously infected by SARS-CoV-2: Systematic review and meta-analysis. Chin. Med. J. 2021;135:145&#x2013;152. doi: 10.1097/CM9.0000000000001892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000001892</ArticleId><ArticleId IdType="pmc">PMC8769121</ArticleId><ArticleId IdType="pubmed">34908003</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery-Smith A., Rowland T.A.J., Patel M., Whitaker H., Iyanger N., Williams S.V., Giddings R., Thompson L., Zavala M., Aiano F., et al. Reinfection with new variants of SARS-CoV-2 after natural infection: A prospective observational cohort in 13 care homes in England. Lancet Healthy Longev. 2021;2:e811&#x2013;e819. doi: 10.1016/S2666-7568(21)00253-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(21)00253-1</ArticleId><ArticleId IdType="pmc">PMC8635459</ArticleId><ArticleId IdType="pubmed">34873592</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhillon R.A., Qamar M.A., Gilani J.A., Irfan O., Waqar U., Sajid M.I., Mahmood S.F. The mystery of COVID-19 reinfections: A global systematic review and meta-analysis. Ann. Med. Surg. 2021;72:103130. doi: 10.1016/j.amsu.2021.103130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2021.103130</ArticleId><ArticleId IdType="pmc">PMC8642249</ArticleId><ArticleId IdType="pubmed">34900250</ArticleId></ArticleIdList></Reference><Reference><Citation>Murchu E.O., Byrne P., Walsh K.A., Carty P.G., Connolly M., De Gascun C., Jordan K., Keoghan M., O&#x2019;Brien K.K., O&#x2019;Neill M., et al. Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review. Rev. Med. Virol. 2020;31:e2162. doi: 10.1002/rmv.2162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2162</ArticleId><ArticleId IdType="pmc">PMC7536965</ArticleId><ArticleId IdType="pubmed">32964627</ArticleId></ArticleIdList></Reference><Reference><Citation>Siracusano G., Brombin C., Pastori C., Cugnata F., Noviello M., Tassi E., Princi D., Cantoni D., Malnati M.S., Maugeri N., et al. Profiling antibody response patterns in COVID-19: Spike S1-reactive IgA signature in the evolution of SARS-CoV-2 infection. Front. Immunol. 2021;12:772239. doi: 10.3389/fimmu.2021.772239.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.772239</ArticleId><ArticleId IdType="pmc">PMC8595940</ArticleId><ArticleId IdType="pubmed">34804064</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M.S., Hansen C.B., Kristiansen M.F., Fjallsbak J.P., Larsen S., Hansen J.L., Jarlhelt I., Perez-Alos L., Steig B.A., Christiansen D.H., et al. SARS-CoV-2 natural antibody response persists for at least 12 months in a nationwide study from the Faroe Islands. Open Forum Infect. Dis. 2021;8:ofab378. doi: 10.1093/ofid/ofab378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab378</ArticleId><ArticleId IdType="pmc">PMC8360234</ArticleId><ArticleId IdType="pubmed">34395713</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Matthews P.C., Stoesser N., Maddox T., Lorenzi L., Studley R., Bell J.I., Newton J.N., Farrar J., Diamond I., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nat. Commun. 2021;12:6250. doi: 10.1038/s41467-021-26479-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26479-2</ArticleId><ArticleId IdType="pmc">PMC8556331</ArticleId><ArticleId IdType="pubmed">34716320</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidner L., Nunhofer V., Jungbauer C., Hoeggerl A.D., Gruner L., Grabmer C., Zimmermann G., Rohde E., Laner-Plamberger S. Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors. Infection. 2021;49:1187&#x2013;1194. doi: 10.1007/s15010-021-01639-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01639-0</ArticleId><ArticleId IdType="pmc">PMC8208066</ArticleId><ArticleId IdType="pubmed">34132990</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidner L., Gansdorfer S., Unterweger S., Weseslindtner L., Drexler C., Farcet M., Witt V., Schistal E., Schlenke P., Kreil T.R., et al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. J. Clin. Virol. 2020;129:104540. doi: 10.1016/j.jcv.2020.104540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104540</ArticleId><ArticleId IdType="pmc">PMC7336952</ArticleId><ArticleId IdType="pubmed">32652475</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi K., Gel Y.R., Brunner E., Konietschke F. nparLD: An R software package for the nonparametric analysis of longitudinal data in factorial experiments. J. Stat. Softw. 2012;50:1&#x2013;23. doi: 10.18637/jss.v050.i12.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v050.i12</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>R-Core-Team . A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2020.</Citation></Reference><Reference><Citation>Vaselli N.M., Hungerford D., Shenton B., Khashkhusha A., Cunliffe N.A., French N. The seroprevalence of SARS-CoV-2 during the first wave in Europe 2020: A systematic review. PLoS ONE. 2021;16:e0250541. doi: 10.1371/journal.pone.0250541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0250541</ArticleId><ArticleId IdType="pmc">PMC8562786</ArticleId><ArticleId IdType="pubmed">34727115</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones J.M., Stone M., Sulaeman H., Fink R.V., Dave H., Levy M.E., Di Germanio C., Green V., Notari E., Saa P., et al. Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020&#x2013;May 2021. JAMA. 2021;326:1400&#x2013;1409. doi: 10.1001/jama.2021.15161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.15161</ArticleId><ArticleId IdType="pmc">PMC8414359</ArticleId><ArticleId IdType="pubmed">34473201</ArticleId></ArticleIdList></Reference><Reference><Citation>Raouf M., Rabeh M., Kaur S., Sharma R., Thottumkal N., Mohammed R. Seroprevalence of IgG anti-SARS-CoV-2 among voluntary blood donors in Dubai: Demographic and risk factors. Dubai Med. J. 2021;4:204&#x2013;211. doi: 10.1159/000517456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000517456</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrotri M., Harris R.J., Rodger A., Planche T., Sanderson F., Mahungu T., McGregor A., Heath P.T., London C.G., Brown C.S., et al. Persistence of SARS-CoV-2 N-antibody response in healthcare workers, London, UK. Emerg. Infect. Dis. 2021;27:1155&#x2013;1158. doi: 10.3201/eid2704.204554.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2704.204554</ArticleId><ArticleId IdType="pmc">PMC8007325</ArticleId><ArticleId IdType="pubmed">33734962</ArticleId></ArticleIdList></Reference><Reference><Citation>Krutikov M., Palmer T., Tut G., Fuller C., Azmi B., Giddings R., Shrotri M., Kaur N., Sylla P., Lancaster T., et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): Prospective cohort study in England. Lancet Healthy Longev. 2022;3:e13&#x2013;e21. doi: 10.1016/S2666-7568(21)00282-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(21)00282-8</ArticleId><ArticleId IdType="pmc">PMC8676418</ArticleId><ArticleId IdType="pubmed">34935001</ArticleId></ArticleIdList></Reference><Reference><Citation>Chansaenroj J., Yorsaeng R., Posuwan N., Puenpa J., Wanlapakorn N., Sudhinaraset N., Sripramote M., Chalongviriyalert P., Jirajariyavej S., Kiatpanabhikul P., et al. Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients. Sci. Rep. 2021;11:23216. doi: 10.1038/s41598-021-02659-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02659-4</ArticleId><ArticleId IdType="pmc">PMC8636620</ArticleId><ArticleId IdType="pubmed">34853374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.C., Wang J.H., Hsueh P.R. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. Int. J. Infect. Dis. 2020;101:314&#x2013;322. doi: 10.1016/j.ijid.2020.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.10.011</ArticleId><ArticleId IdType="pmc">PMC7546669</ArticleId><ArticleId IdType="pubmed">33045429</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang T., Liang B., Fang Y., Lu S., Li S., Wang H., Li H., Yang X., Shen S., Zhu B., et al. Declining levels of neutralizing antibodies against SARS-CoV-2 in convalescent COVID-19 patients one year post symptom onset. Front. Immunol. 2021;12:708523. doi: 10.3389/fimmu.2021.708523.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.708523</ArticleId><ArticleId IdType="pmc">PMC8242354</ArticleId><ArticleId IdType="pubmed">34220870</ArticleId></ArticleIdList></Reference><Reference><Citation>Zietz M., Zucker J., Tatonetti N.P. Associations between blood type and COVID-19 infection, intubation, and death. Nat. Commun. 2020;11:5761. doi: 10.1038/s41467-020-19623-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19623-x</ArticleId><ArticleId IdType="pmc">PMC7666188</ArticleId><ArticleId IdType="pubmed">33188185</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoiland R.L., Fergusson N.A., Mitra A.R., Griesdale D.E.G., Devine D.V., Stukas S., Cooper J., Thiara S., Foster D., Chen L.Y.C., et al. The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. Blood Adv. 2020;4:4981&#x2013;4989. doi: 10.1182/bloodadvances.2020002623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020002623</ArticleId><ArticleId IdType="pmc">PMC7594392</ArticleId><ArticleId IdType="pubmed">33057633</ArticleId></ArticleIdList></Reference><Reference><Citation>Latz C.A., Decarlo C., Boitano L., Png C.Y.M., Patell R., Conrad M.F., Eagleton M., Dua A. Blood type and outcomes in patients with COVID-19. Ann. Hematol. 2020;99:2113&#x2013;2118. doi: 10.1007/s00277-020-04169-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-020-04169-1</ArticleId><ArticleId IdType="pmc">PMC7354354</ArticleId><ArticleId IdType="pubmed">32656591</ArticleId></ArticleIdList></Reference><Reference><Citation>Leaf R.K., Al-Samkari H., Brenner S.K., Gupta S., Leaf D. ABO phenotype and death in critically ill patients with COVID-19. Br. J. Haematol. 2020;190:e204&#x2013;e208. doi: 10.1111/bjh.16984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16984</ArticleId><ArticleId IdType="pmc">PMC7361419</ArticleId><ArticleId IdType="pubmed">32609874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray J.G., Schull M.J., Vermeulen M.J., Park A.L. Association between ABO and Rh blood groups and SARS-CoV-2 infection or severe COVID-19 illness: A population-based cohort study. Ann. Intern. Med. 2020;174:308&#x2013;315. doi: 10.7326/M20-4511.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-4511</ArticleId><ArticleId IdType="pmc">PMC7711653</ArticleId><ArticleId IdType="pubmed">33226859</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Yang Y., Huang H., Li D., Gu D., Lu X., Zheng Z., Liu L., Liu T., Liu Y., et al. Relationship between the ABO blood group and the COVID-19 susceptibility. Clin. Infect. Dis. 2021;73:328&#x2013;331. doi: 10.1093/cid/ciaa1150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1150</ArticleId><ArticleId IdType="pmc">PMC7454371</ArticleId><ArticleId IdType="pubmed">32750119</ArticleId></ArticleIdList></Reference><Reference><Citation>Shokri P., Golmohammadi S., Noori M., Nejadghaderi S.A., Carson-Chahhoud K., Safiri S. The relationship between blood groups and risk of infection with SARS-CoV-2 or development of severe outcomes: A review. Rev. Med. Virol. 2022;32:e2247. doi: 10.1002/rmv.2247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2247</ArticleId><ArticleId IdType="pmc">PMC8209917</ArticleId><ArticleId IdType="pubmed">34997677</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Wang X., Chen J., Cai Y., Deng A., Yang M. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. Br. J. Haematol. 2020;190:24&#x2013;27. doi: 10.1111/bjh.16797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16797</ArticleId><ArticleId IdType="pmc">PMC7267665</ArticleId><ArticleId IdType="pubmed">32379894</ArticleId></ArticleIdList></Reference><Reference><Citation>Boukhari R., Breiman A., Jazat J., Ruvoen-Clouet N., Martinez S., Damais-Cepitelli A., Le Niger C., Devie-Hubert I., Penasse F., Mauriere D., et al. ABO blood group incompatibility protects against SARS-CoV-2 transmission. Front. Microbiol. 2021;12:799519. doi: 10.3389/fmicb.2021.799519.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.799519</ArticleId><ArticleId IdType="pmc">PMC8767008</ArticleId><ArticleId IdType="pubmed">35069504</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzik S., Eliason K., Morris E.B., Kaufman R.M., North C.M. COVID-19 and ABO blood groups. Transfusion. 2020;60:1883&#x2013;1884. doi: 10.1111/trf.15946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15946</ArticleId><ArticleId IdType="pmc">PMC7323215</ArticleId><ArticleId IdType="pubmed">32562280</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudin L., Janvier F., Bylicki O., Dutasta F. ABO blood groups are not associated with risk of acquiring the SARS-CoV-2 infection in young adults. Haematologica. 2020;105:2841&#x2013;2843. doi: 10.3324/haematol.2020.265066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2020.265066</ArticleId><ArticleId IdType="pmc">PMC7716357</ArticleId><ArticleId IdType="pubmed">33256383</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y., Latz C.A., DeCarlo C.S., Lee S., Png C.Y.M., Kibrik P., Sung E., Alabi O., Dua A. Relationship between blood type and outcomes following COVID-19 infection. Semin. Vasc. Surg. 2021;34:125&#x2013;131. doi: 10.1053/j.semvascsurg.2021.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semvascsurg.2021.05.005</ArticleId><ArticleId IdType="pmc">PMC8286549</ArticleId><ArticleId IdType="pubmed">34642032</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P.P., Srivastava A.K., Upadhyay S.K., Singh A., Upadhyay S., Kumar P., Rai V., Shrivastava P., Chaubey G., Serosurveillance Consortium BHU The association of ABO blood group with the asymptomatic COVID-19 cases in India. Transfus. Apher. Sci. 2021;60:103224. doi: 10.1016/j.transci.2021.103224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2021.103224</ArticleId><ArticleId IdType="pmc">PMC8321691</ArticleId><ArticleId IdType="pubmed">34366234</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillon P., Clement M., Sebille V., Rivain J.G., Chou C.F., Ruvoen-Clouet N., Le Pendu J. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology. 2008;18:1085&#x2013;1093. doi: 10.1093/glycob/cwn093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/cwn093</ArticleId><ArticleId IdType="pmc">PMC7108609</ArticleId><ArticleId IdType="pubmed">18818423</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnkob M.B., Pottegard A., Stovring H., Haunstrup T.M., Homburg K., Larsen R., Hansen M.B., Titlestad K., Aagaard B., Moller B.K., et al. Reduced prevalence of SARS-CoV-2 infection in ABO blood group O. Blood Adv. 2020;4:4990&#x2013;4993. doi: 10.1182/bloodadvances.2020002657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020002657</ArticleId><ArticleId IdType="pmc">PMC7594382</ArticleId><ArticleId IdType="pubmed">33057631</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleers M., Breiman A., Daubie V., Maggetto C., Barreau I., Besse T., Cl&#xe9;menceau B., Ruvo&#xeb;n-Clouet N., Fils J.-F., Maillart E., et al. COVID-19 and blood groups: ABO antibody levels may also matter. Int. J. Infect. Dis. 2021;104:242&#x2013;249. doi: 10.1016/j.ijid.2020.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.12.025</ArticleId><ArticleId IdType="pmc">PMC7832075</ArticleId><ArticleId IdType="pubmed">33326874</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson M.A., Quandelacy T.M., Kada S., Prasad P.V., Steele M., Brooks J.T., Slayton R.B., Biggerstaff M., Butler J.C. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw. Open. 2021;4:e2035057. doi: 10.1001/jamanetworkopen.2020.35057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.35057</ArticleId><ArticleId IdType="pmc">PMC7791354</ArticleId><ArticleId IdType="pubmed">33410879</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch K.M., Cabeen R.P., Toga A.W., Clark K.A. Magnitude and timing of major white matter tract maturation from infancy through adolescence with NODDI. NeuroImage. 2020;212:116672. doi: 10.1016/j.neuroimage.2020.116672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2020.116672</ArticleId><ArticleId IdType="pmc">PMC7224237</ArticleId><ArticleId IdType="pubmed">32092432</ArticleId></ArticleIdList></Reference><Reference><Citation>Amjadi M.F., O&#x2019;Connell S.E., Armbrust T., Mergaert A.M., Narpala S.R., Halfmann P.J., Bashar S.J., Glover C.R., Heffron A.S., Taylor A., et al. Specific COVID-19 symptoms correlate with high antibody levels against SARS-CoV-2. Immunohorizons. 2021;5:466&#x2013;476. doi: 10.4049/immunohorizons.2100022.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.2100022</ArticleId><ArticleId IdType="pmc">PMC8452279</ArticleId><ArticleId IdType="pubmed">34398806</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141&#x2013;154. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta O.P., Bhandari P., Raut A., Kacimi S.E.O., Huy N.T. Coronavirus disease (COVID-19): Comprehensive review of clinical presentation. Front. Public Health. 2020;8:582932. doi: 10.3389/fpubh.2020.582932.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2020.582932</ArticleId><ArticleId IdType="pmc">PMC7844320</ArticleId><ArticleId IdType="pubmed">33520910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai P.-H., Lai W.-Y., Lin Y.-Y., Luo Y.-H., Chen H.-K., Chen Y.-M., Lai Y.-C., Kuo L.-C., Chen S.-D., Chang K.-J., et al. Clinical manifestation and disease progression in COVID-19 infection. J. Chin. Med. Assoc. 2021;84:3&#x2013;8. doi: 10.1097/JCMA.0000000000000463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCMA.0000000000000463</ArticleId><ArticleId IdType="pubmed">33230062</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J., Okyay R., Licht W., Hurley D. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10:763. doi: 10.3390/pathogens10060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue J.K., Franko N.M., McCulloch D.J., McDonald D., Magedson A., Wolf C.R., Chu H.Y. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw. Open. 2021;4:e210830. doi: 10.1001/jamanetworkopen.2021.0830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>